Working diagnosis: Hepatic Encephalopathy

• Grade I: sleep reversal, mild confusion, irritability, tremor, asterixis
• Grade II: lethargy, disorientation, inappropriate behavior, asterixis
• Grade III: somnolence, severe confusion, aggressive behavior, asterixis
• Grade IV: coma

How breathlessness and drowsiness commonly link in DCLD

Practical approach to this patient

1. Confirm HE: check for asterixis, sleep-wake reversal, disorientation; exclude other causes of altered sensorium (hypoglycemia, intracranial event, drug effect).
2. Look specifically for a precipitant that also explains breathlessness:
   • CBC/hemoglobin - anemia from occult/overt GI bleed
   • Ascitic fluid analysis - rule out SBP (neutrophil count, culture)
   • Chest examination/CXR - hepatic hydrothorax, tense ascites splinting the diaphragm, or evidence of pneumonia/aspiration
   • ABG/oxygen saturation - hypoxemia from hepatopulmonary syndrome or hydrothorax
   • Electrolytes and renal function - hyponatremia, hypokalemia, azotemia
   • Review medication list for recent sedatives/opioids or diuretic overuse
3. Treat the precipitant while starting standard HE management (lactulose +/- rifaximin, correcting electrolytes, treating infection, therapeutic paracentesis/thoracentesis if tense ascites or large hydrothorax is contributing to respiratory compromise).

Targeted work-up by precipitant

• CBC (falling Hb/Hct), reticulocyte count
• Coagulation profile (INR/PT), platelet count
• Stool occult blood / melena on PR exam
• Urea:creatinine ratio (disproportionately raised urea from blood digestion)
• Upper GI endoscopy - the confirmatory test if bleed is suspected
• Ammonia can be secondarily elevated because gut bacteria convert the nitrogen load from digested blood into ammonia (Rosen's Emergency Medicine, p. 2656)

• Diagnostic paracentesis: ascitic fluid absolute neutrophil (PMN) count > 250 cells/mm3 confirms SBP; culture may be negative in ~60% (Bailey and Love's Short Practice of Surgery; Sabiston Textbook of Surgery)
• Blood cultures, CBC (leukocytosis), CRP/procalcitonin
• Ascitic fluid protein/glucose/LDH to exclude secondary peritonitis

• CXR - unilateral (usually right-sided) pleural effusion, often with elevated hemidiaphragm
• Diagnostic thoracentesis: transudate, low protein concentration, pleural fluid/serum protein ratio <0.5 (Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Grainger & Allison's Diagnostic Radiology)
• If infected fluid suspected: pleural fluid PMN count >250/mm3 (or culture-positive with any PMN elevation) confirms spontaneous bacterial empyema, the pleural analog of SBP (Fishman's Pulmonary Diseases and Disorders, p. 1171)

• Arterial blood gas: PaO2 <80 mmHg or A-a gradient >15 mmHg on room air
• Contrast (bubble) echocardiography: shows delayed appearance of bubbles in the left heart, confirming intrapulmonary vascular shunting (Goldman-Cecil Medicine, p. 4074; Murray & Nadel's Textbook of Respiratory Medicine)
• Macroaggregated albumin lung perfusion scan if echo is positive but etiology unclear
• Pulse oximetry is notably insensitive for screening - don't rely on it alone

• Serum sodium, potassium, bicarbonate (hyponatremia, hypokalemic alkalosis from diuretics classically precipitates HE)
• Serum creatinine/urea, urine output - screen for hepatorenal syndrome or prerenal azotemia

• Clinical grading (asterixis, EEG showing slow triphasic waves) is more useful than ammonia
• Serum ammonia can support the diagnosis but does not correlate with severity and is neither sensitive nor specific - it should not be used alone to confirm or exclude HE (The Washington Manual of Medical Therapeutics, p. 747; Symptom to Diagnosis, p. 8183)

Practical bedside sequence

1. CBC + coagulation profile + stool exam (bleed)
2. Diagnostic ascitic tap with cell count/culture (SBP) - do this early, low threshold even without abdominal signs
3. CXR +/- diagnostic thoracentesis if effusion present (hydrothorax vs empyema)
4. ABG/room-air saturation; if hypoxic and no effusion/consolidation explains it, proceed to contrast echocardiography (hepatopulmonary syndrome)
5. Electrolytes, renal function
6. EEG/clinical grading for HE severity; ammonia is supportive, not diagnostic

Guideline Landscape for Hepatic Encephalopathy (HE)

• Vilstrup H, Amodio P, Bajaj J, et al. "Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the AASLD and EASL." Hepatology 2014;60:715-735. This is still listed as AASLD's current guideline on hepatic encephalopathy (no newer joint update has been issued since 2014).

• EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-824. [PMID: 35724930] - with a published erratum [PMID: 37758523].

• Bajaj JS, Jakab SS, Jesudian AB, et al. "ACG Clinical Guideline: Hepatic Encephalopathy." Am J Gastroenterol. 2026;121(3):588-618. This is the most recent English-language HE guideline overall, issued by the American College of Gastroenterology rather than AASLD/EASL.

• Bajaj JS, Lauridsen M, Tapper EB, et al. "Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus." Am J Gastroenterol. 2020;115(7):989-1002.

Precipitants (unchanged core list across 2014 -> 2022 versions)

• Infection (SBP, UTI, pneumonia, cellulitis)
• GI bleeding
• Electrolyte disturbance (hyponatremia, hypokalemia) and dehydration - often diuretic- or diarrhea-induced
• Constipation
• Medication non-adherence (missed lactulose/rifaximin) or use of sedatives/opioids/benzodiazepines
• Renal dysfunction/azotemia
• Portosystemic shunting (TIPS or spontaneous)
• Progressive hepatocellular dysfunction/superimposed acute injury

Management recommendations (2022 EASL update, building on 2014 AASLD/EASL)

1. Treat the precipitant first - this remains the single highest-priority action; HE will not resolve reliably until the trigger is corrected.
2. Lactulose remains first-line for episodic overt HE (titrated to 2-3 soft stools/day).
3. Rifaximin is added for secondary prophylaxis after a second episode of overt HE, on top of lactulose - this recommendation strengthened in the 2022 EASL update relative to 2014.
4. Do not protein-restrict - normal protein intake (1.2-1.5 g/kg/day) with adequate calories is recommended; chronic protein restriction worsens sarcopenia and outcomes. Branched-chain amino acids (BCAAs) can be used in protein-intolerant patients.
5. Nutritional/sarcopenia management is explicitly emphasized in the 2022 update (and cross-referenced by the newer 2025 ACG malnutrition guideline, PMID 40314389).
6. L-ornithine L-aspartate (LOLA) and polyethylene glycol are discussed as adjuncts with variable evidence strength; not universally mandated.
7. TIPS-related HE: guidelines note that shunt reduction/embolization can be considered for refractory post-TIPS HE.
8. Covert/minimal HE should be screened for in patients with impaired quality of life or driving/occupational safety concerns, using psychometric tests (PHES) or critical flicker frequency, per both EASL 2022 and the newer Chinese Consensus on covert HE (2025, PMID 40891110).

Recent evidence check (systematic reviews/meta-analyses, last 2 years)

• Cochrane review 2026 [PMID 41542879] - BCAAs for HE in cirrhosis; reaffirms benefit for HE but with low-to-moderate certainty evidence, consistent with guideline recommendations rather than contradicting them.
• Meta-analysis 2025 [PMID 40812534] - PPI use associated with increased HE risk in cirrhotic patients; this is a newer signal not explicitly addressed in the 2014/2022 guidelines and worth flagging when reviewing a patient's medication list for precipitants.
• Meta-analysis 2024 [PMID 37856206] - confirms high prevalence of covert/minimal HE in cirrhosis, supporting the screening emphasis added in 2022 EASL guidance.